October 09, 2025

AbbVie US + EU Golden Ticket 2025 – Apply by November 7, 2025

AbbVie US + EU Golden Ticket 2025 – Apply by November 7, 2025
Go back

AbbVie is launching a US and Europe based golden ticket. The award consists of one golden ticket, which provides one year of fully paid individual bench, a desk and membership at one of BioLabs’ operating locations in the US, France or Germany. The award is intended for early-stage biotech companies developing therapeutics (not devices) in the field of migraine.

Additional eligibility requirements are listed below.

More Information

Application requirements 
AbbVie is looking for early-stage biotech companies that fit the following criteria: 

  • Have primary business location in US, France or Germany​
  • Be an early stage-startup focused on developing novel therapeutic approaches for migraine that could include both central and peripheral mechanisms for treating acute migraine and migraine prevention.​
  • Related research areas in pain with potential application(s) to migraine will also be considered.
  • Excluded are devices, neuromodulation technologies and similar technologies.
  • For additional requirements refer to the Terms and Conditions document.

Therapeutic focus of this call for applications: Migraine

Our latest News

discover more
RHEACELL makes second location in Heidelberg visible

RHEACELL makes second location in Heidelberg visible

Heidelberg, January 28, 2026 – RHEACELL GmbH & Co. KG is continuing to expand its presence in Heidelberg and moved into a second location in the Pfaffengrund district in August last year. At the start of the year, the location is now also becoming visible to the outside world: this week, the company logo will […]

read more
TUM Researchers receive two ERC Grants

TUM Researchers receive two ERC Grants

The European Research Council’s (ERC) Proof of Concept Grants are designed to help researchers turn their findings into real‑world innovations. Two ERC‑funded follow‑up projects at TUM will each receive approximately 150,000 euros in support. The projects focus on virus‑driven cancer treatments and new ways to supply electrons for enzyme‑based technologies. Researchers at TUM have secured […]

read more
Weight Loss in Cancer: Organs Respond to the Disease in a Coordinated Way

Weight Loss in Cancer: Organs Respond to the Disease in a Coordinated Way

Cachexia is a metabolic disorder that causes uncontrolled weight loss and muscle wasting in chronic diseases and cancer. A new study by Helmholtz Munich, in collaboration with the Institute of Physiology of the Czech Academy of Sciences in Prague, Heidelberg University Hospital, the German Center for Diabetes Research (DZD), and the German Center for Cardiovascular […]

read more

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp